Vimarsana
Biggest News Aggregation in the World

Page 2 - Scott Kellen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Scott Kellen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Scott Kellen Today - Breaking & Trending Today

DiaMedica Therapeutics (DMAC) Set to Announce Earnings on Monday - Vimarsana News

DiaMedica Therapeutics (DMAC) Set to Announce Earnings on Monday

DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Monday, August 14th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last announced its quarterly earnings data on Monday, May 15th. The […]

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2022 Earnings Call Transcript - Vimarsana News

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2022 Earnings Call Transcript

Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics ReMEDy2 Update Conference Call.

DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations - Vimarsana News

DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations

Leadership Team Continues to Expand with Addition of Key Leader in Clinical OperationsMINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appoint...

DiaMedica Therapeutics to Participate in the BTIG Biotechnology Conference 2022 - Vimarsana News

DiaMedica Therapeutics to Participate in the BTIG Biotechnology Conference 2022

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company’s management team will be participating in one-on-one meetings at the upcoming B...

DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer - Vimarsana News

DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer

Executive with Extensive Track Record in Neurology and Rare Disease Drug DevelopmentMINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointme...